Blank Rome Represents Intellipharmaceutics International Inc. in an Underwritten Public Offering
Blank Rome represented Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, in an underwritten public offering of 3,229,814 units at a price of US $1.61 per unit for gross proceeds of US $5.2 million.